Close Menu

NEW YORK – Paris-based biotech Transgene on Thursday said that the first head-and-neck cancer patient has been dosed with its individualized immunotherapy, TG4050, in a Phase I trial.

The cancer vaccine is personalized to each patient based on Transgene's Myvac viral vector-based immunotherapy platform and NEC's artificial intelligence-based Neoantigen Prediction System.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.